In this review we will focus on host factors known to impact hepatitis B virus (HBV) replication as current or potential targets for therapeutic intervention. Some immunotherapeutic strategies will be discussed because they have the potential to activate interferon-mediated clearance of HBV, but attention will also be paid to host machinery and proteins that silence covalently closed circular DNA, destabilize viral RNA, or disrupt entry and trafficking of HBV virions. Many of these are in the early stages of development, but may represent novel avenues to reduce HBV burden when combined with nucleos(t)ide analogues.

Keywords:
Hepatitis B virus, Therapy, Immunotherapy
1.
Marcellin P, Gane E, Buti M, et al: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475.
2.
Zoulim F, Perrillo R: Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48:S2-S19.
3.
Boni C, Laccabue D, Lampertico P, et al: Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012;143:963-973.e9.
4.
Woo G, Tomlinson G, Nishikawa Y, et al: Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218-1229.
5.
Wursthorn K, Jung M, Riva A, et al: Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52:1611-1620.
6.
van Bömmel F, de Man RA, Wedemeyer H, et al: Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleos(t)ide analogues. Hepatology 2009;51:73-80.
7.
Guidotti LG: Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829.
8.
Werle Lapostolle B, Bowden S, Locarnini S, et al: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-1758.
9.
Lutgehetmann M, Volz T, Köpke A, et al: In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010;52:16-24.
10.
Fox AN, Terrault NA: The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 2012;56:1189-1197.
11.
Volz T, Allweiss L, Ben MBarek M, et al: The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013;58:861-867.
12.
Petersen J, Dandri M, Mier W, et al: Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-341.
13.
Meier A, Mehrle S, Weiss TS, Mier W, Urban S: Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology 2013;58:31-42.
14.
Mao R, Nie H, Cai D, et al: Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog 2013;9:e1003494.
15.
Liang G, Kitamura K, Wang Z, et al: RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase. Proc Natl Acad USA 2013;110:2246-2251.
16.
Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP: Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 2005;102:8321-8326.
17.
Vartanian JP, Henry M, Marchio A, et al: Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 2010;6:e1000928.
18.
Bonvin M, Achermann F, Greeve I, et al: Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006;43:1364-1374.
19.
Baumert TF, Rösler C, Malim MH, von Weizsäcker F: Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 2007;46:682-689.
20.
Nguyen DH, Gummuluru S, Hu J: Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 2007;81:4465-4472.
21.
Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al: Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-1228.
22.
Hu J, Flores D, Toft D, Wang X, Nguyen D: Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J Virol 2004;78:13122-13131.
23.
Hu J, Seeger C: Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci USA 1996;93:1060-1064.
24.
Jhaveri K, Modi S: HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol 2012;65:471-517.
25.
Cai D, Mills C, Yu W, et al: Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012;56:4277-4288.
26.
Mao R, Zhang J, Jiang D, et al: Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol 2010;85:1048-1057.
27.
McCaffrey AP, Nakai H, Pandey K, et al: Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003;21:639-644.
28.
Morrissey DV, Lockridge JA, Shaw L, et al: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-1007.
29.
Wooddell CI, Rozema DB, Hossbach M, et al: Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 2013;21:973-985.
30.
Perrillo R: Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009;49(5 suppl):S103-S111.
31.
Allweiss L, Volz T, Lutgehetmann M, Giersch K, Bornscheuer T, Lohse AW, et al.: Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol 2014;60:500-507.
32.
Liu F, Campagna M, Qi Y, et al: Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 2013;9:e1003613.
33.
Belloni L, Allweiss L, Guerrieri F, et al: IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012;122:529-537.
34.
Lutgehetmann M, Bornscheuer T, Volz T, et al: Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology 2011;140:2074-2083.e1-2.
35.
Tan AT, Hoang LT, Chin D, et al: Reduction of HBV replication prolongs the early immunological response to IFNα therapy. J Hepatol 2014;60:54-61.
36.
Micco L, Peppa D, Loggi E, et al: Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013;58:225-233.
37.
Ji C, Sastry KS, Tiefenthaler G, et al: Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies. Hepatology 2012;56:2027-2038.
38.
Penna A, Laccabue D, Libri I, et al: Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. J Hepatol 2012;56:1239-1246.
39.
Isogawa M, Robek MD, Furuichi Y, Chisari FV: Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79:7269-7272.
40.
Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV: Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol 2002;169:5188-5195.
41.
McClary H, Koch R, Chisari FV, Guidotti LG: Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000;74:2255-2264.
42.
Lanford RE, Guerra B, Chavez D, et al: GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013;144:1508-1517.e1-10.
43.
Tang XZ, Jo J, Tan AT, et al: IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol 2013;190:3142-3152.
44.
Bertoletti A, Gehring AJ: Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog 2013:19;9:e1003784.
45.
Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, et al: Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014: 2;10:e1003856.
46.
Tan AT, Loggi E, Boni C, et al: Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol 2008;82:10986-10997.
47.
Kidd-Ljunggren K, Miyakawa Y, Kidd AH: Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267-1280.
48.
Gehring AJ, Haniffa M, Kennedy PT, et al: Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest 2013;123:3766-3776.
49.
Xu DZ, Wang XY, Shen XL, et al: Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 2013;59:450-456.
50.
Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV: CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog 2013;9:e1003490.
51.
Huang LR, Wohlleber D, Reisinger F, et al: Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 2013;14:574-583.
52.
Tavis JE, Gehring AJ, Hu Y: How further suppression of virus replication could improve current HBV treatment. Expert Rev Anti Infect Ther 2013;11:755-757.
53.
Block TM, Gish R, Guo H, et al: Chronic hepatitis B: what should be the goal for new therapies? Antivir Res 2013;98:27-34.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.